Cannabis for Seizures UK – CBD and Epilepsy Evidence

Cannabis for Seizures UK: CBD and Epilepsy Evidence

The use of cannabis and cannabidiol (CBD) for treating seizures has emerged as one of the most promising medical applications of cannabis in the United Kingdom. With epilepsy affecting approximately 600,000 people across the UK, many patients and healthcare professionals are increasingly interested in understanding the evidence surrounding cannabis-based treatments. This comprehensive guide explores the current research, legal status, and practical considerations for using cannabis to manage seizures in the UK.

Understanding Seizures and Epilepsy in the UK

Epilepsy is a neurological condition characterised by recurrent seizures, affecting around 1 in 100 people in the UK. Seizures occur when there is abnormal electrical activity in the brain, causing temporary disruptions to normal brain function. Despite the availability of over 20 anti-epileptic drugs (AEDs), approximately 30% of people with epilepsy find their seizures resistant to conventional treatment.

This significant proportion of treatment-resistant epilepsy patients has prompted researchers and clinicians to explore alternative therapeutic options, including cannabis-based medicines. The search for effective alternatives is particularly important for individuals experiencing multiple daily seizures that impact their quality of life and safety.

The Science Behind Cannabis and Seizure Control

Cannabis contains over 100 active compounds called cannabinoids, with cannabidiol (CBD) and tetrahydrocannabinol (THC) being the most extensively researched. CBD has become the primary focus of seizure research due to its non-intoxicating properties and anticonvulsant effects.

The mechanism by which CBD reduces seizures involves several pathways. CBD interacts with serotonin receptors, vanilloid receptors, and adenosine signalling systems in the brain. These interactions help stabilise electrical activity and reduce the likelihood of seizures occurring. Unlike THC, CBD does not produce the euphoric “high” associated with cannabis, making it more suitable for medical use in seizure management.

Research suggests that CBD may work synergistically with other cannabinoids present in cannabis, though CBD alone has demonstrated significant anticonvulsant potential. This entourage effect—where multiple cannabis compounds work together—may enhance therapeutic benefits compared to isolated CBD.

Clinical Evidence for Cannabis-Based Seizure Treatment

Several landmark studies have demonstrated the efficacy of CBD in reducing seizure frequency. The most notable research involves Epidiolex (cannabidiol oral solution), which has shown promising results in clinical trials. In 2018, a randomised controlled trial published in the New England Journal of Medicine demonstrated that CBD reduced seizure frequency by approximately 39% in patients with Dravet syndrome, a severe childhood epilepsy.

For Lennox-Gastaut syndrome, another severe form of childhood epilepsy, CBD treatment resulted in a median reduction of seizure frequency of 41.9% in one pivotal study. These results represent significant improvements compared to many conventional treatments, particularly for these drug-resistant epilepsy variants.

Beyond these specific conditions, preliminary evidence suggests potential benefits across various epilepsy types. However, researchers emphasise that more large-scale, long-term studies are necessary to fully understand CBD’s role in epilepsy management and to identify optimal dosing strategies for different patient populations.

Legal Status of Cannabis for Seizures in the UK

In the UK, cannabis remains a Schedule II controlled substance under the Misuse of Drugs Act 1971. However, in 2018, the Home Office rescheduled cannabis-based products for medicinal use, allowing doctors to prescribe cannabis medicines to patients with specific conditions under strict circumstances.

Epiliolex (Epidiolex) received approval as a prescription medicine from the Medicines and Healthcare products Regulatory Agency (MHRA) in September 2019. This makes it legally available for patients with severe epilepsy who have not responded to other treatments. The National Institute for Health and Care Excellence (NICE) has provided guidance on its use, particularly recommending it for Dravet syndrome and Lennox-Gastaut syndrome.

To access cannabis-based seizure treatments, patients must have a diagnosis confirmed by a specialist neurologist and must have tried conventional anti-epileptic drugs without sufficient benefit. Private prescriptions are also available, though these are considerably more expensive than NHS provision.

Accessing Cannabis-Based Seizure Treatment in the UK

Patients wishing to explore cannabis-based treatment for seizures should initiate a discussion with their neurology specialist. NHS access typically requires referral to a specialist centre with experience in cannabis-based medicines. Several NHS trusts across England, Scotland, Wales, and Northern Ireland now have clinics dedicated to prescribing these medicines.

The consultation process involves comprehensive assessment of the patient’s medical history, seizure type, previous treatment responses, and overall health status. Specialists will discuss potential benefits and risks, including possible side effects and interactions with current medications.

If treatment is initiated, patients receive regular follow-up appointments to monitor seizure frequency, side effects, and overall efficacy. Dosing is typically individualised and adjusted based on patient response and tolerance.

Potential Side Effects and Safety Considerations

While CBD is generally well-tolerated, side effects can occur. Common adverse effects include fatigue, diarrhoea, appetite changes, and weight loss. More serious but rare side effects include liver function abnormalities, particularly when used alongside certain anti-epileptic medications.

CBD can interact with numerous medications, particularly those metabolised by the cytochrome P450 enzyme system. Patients taking blood thinners, immunosuppressants, or certain other medications must have careful medical supervision when starting CBD treatment.

Pregnancy and breastfeeding represent relative contraindications, as safety data remains limited. Women of childbearing age should discuss contraception and family planning with their healthcare provider before commencing treatment.

Current UK Research and Future Perspectives

British research institutions are actively investigating cannabis-based treatments for seizures. Several universities and NHS trusts are conducting ongoing trials examining CBD’s effectiveness across different epilepsy types and exploring optimal dosing strategies for the UK population.

Future developments may include the development of additional cannabis-based formulations, combination therapies, and personalised medicine approaches that identify which patients are most likely to benefit from treatment. Researchers are also investigating whether CBD might prevent the development of epilepsy in at-risk populations.

Key Takeaways for UK Patients

Cannabis-based medicines, particularly CBD, represent a valuable option for patients with drug-resistant seizures. Strong clinical evidence supports their use, particularly for Dravet and Lennox-Gastaut syndromes. Legal access in the UK is possible through NHS prescription or private consultation with appropriately qualified specialists.

Patients interested in exploring this treatment option should consult with their neurology specialist to determine suitability and discuss potential benefits and risks. With careful medical supervision and appropriate patient selection, cannabis-based seizure treatment offers hope for many individuals living with difficult-to-control epilepsy across the United Kingdom.

“`

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Medical cannabis is a prescription-only medicine in the UK. Always consult a qualified healthcare professional. CannaZen is an information platform, not a medical provider.